RUNX2 and neoplasm: AML3 and AML5 showed heightened enrichment of pathways involved in anti-tumor response and lipid metabolism, including the interferon-gamma response, oxidative phosphorylation, adipogenesis, interferon-alpha response, and fatty acid metabolism pathways.